Evidence map›Paper›PMID 12454687›Full record

ReviewInternational journal of impotence research2002

Gene expression in Peyronie's disease.

N F Gonzalez-Cadavid, T R Magee, M Ferrini, A Qian, D Vernet, J Rajfer

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in International journal of impotence research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03815331 (Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03815331 phase4completednot on this mapstarted 2019, after this paper: background citation

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease

TypeinterventionalSponsorMen's Health BostonRan2019 to 2020Enrolled20ConditionsPeyronie's Disease (PD)ArmsXiaflex®, Aveed
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. The contribution of the immune system to genitourinary fibrosis.Experimental biology and medicine (Maywood, N.J.) · 2022
    Article
  12. Review
  13. Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases.Oxidative medicine and cellular longevity · 2021
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

N F Gonzalez-CadavidDepartment of Urology, UCLA School of Medicine, Los Angeles, California, USA. ncadavid@ucla.edu
T R Magee
M Ferrini
A Qian
D Vernet
J Rajfer
UCLA Medical Center · USUniversity of California, Los Angeles · USHarbor–UCLA Medical Center · US

Funding

RESEARCH INFORMATICS COREG12RR003026 · NCRR · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI BAKER, RICHARD S. · 1986 to 2004
$11.5M
ERECTILE DYSFUNCTION AND NITRIC OXIDE SYNTHASE IN AGINGR01DK053069 · NIDDK · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI GONZALEZ-CADAVID, NESTOR F · 1999 to 2006
$1.6M
NCRR NIH HHS G12RR-03026NIDDK NIH HHS R01DK-53069
6 · The paper itself

Abstract

Currently, surgical intervention is the only efficacious treatment for Peyronie's disease (PD), a fibromatosis of the tunica albuginea of the penis. Therapies based on the molecular pathways for this disease could provide alternatives to surgical treatment but only recently has the pathophysiology of the Peyronie's disease plaque been investigated at the molecular level. In this review, we examine the current knowledge of gene expression in the PD plaque and the relationship of PD with other fibrotic conditions such as Dupytren's disease. TGFbeta1, along with other growth factors, pro-fibrotic genes, and collagen, are expressed in fibroblasts and myofibroblasts. Myofibroblasts are normally involved in wound contracture and largely eliminated via apoptosis during the late stages of wound remodeling. In the PD plaque, however, these cells persist and may play an important role in the PD plaque fibrosis. The expression levels of TGFbeta1 and pro- and anti-fibrotic gene products, along with the nitric oxide/reactive oxygen species (NO/ROS) ratio in the tunica albuginea, appear to be essential for the formation and progression of the PD plaque and effect the expression of multiple genes. This can be assessed with the recently developed DNA-based chip arrays and results with the PD plaque have been encouraging. OSF-1 (osteoblast recruitment), MCP-1 (macrophage recruitment), procollagenase IV (collagenase degradation), and other fibrotic genes have been identified as being possible candidate regulatory genes. Finally, possible therapeutic avenues for gene-based therapy in the treatment of PD are discussed that may eventually reduce the need for surgical intervention.

Indexed as

AnimalsFibrosisGene ExpressionHumansMalePenile Induration

Identifiers

PMID12454687
OpenAlexW2334785913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.